MiNK - INKT Net earnings per share for the last four quarters

Official company branding of MiNK (INKT)

The MiNK Therapeutics, Inc. (INKT) price chart illustrates the EPS TTM trend, which currently stands at 25.50. The business relies on partnerships with oncology centers to develop advanced T-cell therapies. The brand's high authority in immuno-oncology is evidenced by the success of iNKT therapy. The company is currently developing a closed clinical trial environment for patients with solid tumors under strict FDA supervision.

MiNK Therapeutics (INKT) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

INKT (MiNK Therapeutics): analytical breakdowns and indicator data

Initial company analysis:INKT, MiNK
Mass-produced product of minktherapeutics.com

This indicator measures the annual earnings per share (EPS) growth over the last twelve months, allowing for an assessment of business scaling efficiency relative to market capitalization. Analyzing the historical YoY ttm net income per share growth rate helps identify asset undervaluation, which is particularly critical for MiNK Therapeutics, Inc. (INKT) as it implements resource-saving and eco-friendly drug synthesis methods in cell therapy.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months